Hierarchical Computed Tomography Scoring Systems Cannot Discriminate Between Reversible Bronchiectasis and Mucus Plugs

Gaël Dournes^{1

2

3}, Ilyes Benlala^{1

2

3}

Affiliations

¹ University Bordeaux and.
² Institut National de la Santé Et de la Recherche Médicale, Centre de Recherche Cardio-Thoracique de Bordeaux, Pessac, France; and.
³ CHU de Bordeaux, Service d'Imagerie Thoracique et Cardiovasculaire, Service d'Exploration Fonctionnelle Respiratoire, Pessac, France.

Comment

Gaël Dournes et al. Am J Respir Crit Care Med. 2024.

. 2024 Apr 15;209(8):1038-1039.

doi: 10.1164/rccm.202311-2124LE.

Gaël Dournes^{1

2

3}, Ilyes Benlala^{1

2

3}

¹ University Bordeaux and.
² Institut National de la Santé Et de la Recherche Médicale, Centre de Recherche Cardio-Thoracique de Bordeaux, Pessac, France; and.
³ CHU de Bordeaux, Service d'Imagerie Thoracique et Cardiovasculaire, Service d'Exploration Fonctionnelle Respiratoire, Pessac, France.

No abstract available

Comment in

Reply to Dournes and Benlala: Hierarchical Computed Tomography Scoring Systems Cannot Discriminate Between Reversible Bronchiectasis and Mucus Plugs.
McNally P, Davies J, Ciet P, Tiddens H. McNally P, et al. Am J Respir Crit Care Med. 2024 Apr 15;209(8):1039-1040. doi: 10.1164/rccm.202311-2199LE. Am J Respir Crit Care Med. 2024. PMID: 38354409 Free PMC article. No abstract available.

Improvement in Lung Clearance Index and Chest Computed Tomography Scores with Elexacaftor/Tezacaftor/Ivacaftor Treatment in People with Cystic Fibrosis Aged 12 Years and Older - The RECOVER Trial.
McNally P, Lester K, Stone G, Elnazir B, Williamson M, Cox D, Linnane B, Kirwan L, Rea D, O'Regan P, Semple T, Saunders C, Tiddens HAWM, McKone E, Davies JC; RECOVER Study Group. McNally P, et al. Am J Respir Crit Care Med. 2023 Nov 1;208(9):917-929. doi: 10.1164/rccm.202308-1317OC. Am J Respir Crit Care Med. 2023. PMID: 37703083 Clinical Trial.

1. McNally P, Lester K, Stone G, Elnazir B, Williamson M, Cox D, et al. RECOVER Study Group Improvement in lung clearance index and chest computed tomography scores with elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis aged 12 years and older: the RECOVER trial. Am J Respir Crit Care Med . 2023;208:917–929. - PubMed
1. Rosenow T, Oudraad MCJ, Murray CP, Turkovic L, Kuo W, de Bruijne M, et al. Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST CF) PRAGMA-CF: a quantitative structural lung disease computed tomography outcome in young children with cystic fibrosis. Am J Respir Crit Care Med . 2015;191:1158–1165. - PubMed
1. Middleton PG, Simmonds NJ. Cystic fibrosis modulator therapy can reverse cystic bronchiectasis. Respirol Case Rep . 2023;11:e01172. - PMC - PubMed
1. Gushue C, Eisner M, Bai S, Johnson T, Holtzlander M, McCoy K, et al. Impact of elexacaftor–tezacaftor–ivacaftor on lung disease in cystic fibrosis. Pediatr Pulmonol . 2023;58:2308–2316. - PubMed
1. David M, Benlala I, Bui S, Benkert T, Berger P, Laurent F, et al. Longitudinal evaluation of bronchial changes in cystic fibrosis patients undergoing elexacaftor/tezacaftor/ivacaftor therapy using lung MRI with ultrashort echo‐times. J Magn Reson Imaging . 2023 doi: 10.1002/jmri.29041. - DOI - PubMed